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Asthma-related inflammation promotes 
lung metastasis of breast cancer cells 
through CCL11–CCR3 pathway
S. Bekaert1, N. Rocks1, C. Vanwinge1, A. Noel1 and D. Cataldo1,2* 
Abstract 
Background: Mechanisms that preclude lung metastasis are still barely understood. The possible consequences of 
allergic airways inflammation on cancer dissemination were studied in a mouse model of breast cancer.
Methods: Balb/c mice were immunized and daily exposed to ovalbumin (OVA) from day 21. They were subcutane-
ously injected with 4T1 mammary tumor cells on day 45 and sacrificed on day 67. Lung metastases were measured by 
biophotonic imaging (IVIS® 200 Imaging System) and histological measurement of tumor area (Cytomine software). 
Effects of CCL11 were assessed in vivo by intratracheal instillations of recCCL11 and in vitro using Boyden chambers. 
CCR3 expression on cell surface was assessed by flow cytometry.
Results: The extent of tumor metastases was significantly higher in lungs of OVA-exposed mice and increased levels 
of CCL11 expression were measured after OVA exposure. Migration of 4T1 cells and neutrophils was stimulated in vitro 
and in vivo by recCCL11. 4T1 cells and neutrophils express CCR3 as shown by flow cytometry and a selective CCR3 
antagonist (SB-297006) inhibited the induction of 4T1 cells migration and proliferation in response to recCCL11.
Conclusions: Allergic inflammation generated by exposure to allergens triggers the implantation of metastatic cells 
from primary breast tumor into lung tissues plausibly in a CCL11–CCR3-dependent manner. This indicates that asthma 
related inflammation in lungs might be a risk factor for lung metastasis in breast cancer patients.
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Background
Asthma is one of the most frequent chronic diseases, 
affecting ∼300 million people worldwide according to 
The World Health Organization [1]. It is a complex dis-
order of the respiratory system that causes bronchial 
inflammation, airway remodeling and hyperresponsive-
ness [2]. It has been hypothesized that this chronic con-
dition might be a risk factor in developing lung cancer 
[3], especially in non-smokers [4], and that it might also 
lead to metastatic dissemination. Indeed, it is now well 
accepted that microenvironment is an important com-
ponent in the metastatic process [5]. Based on a Surgi-
cal Breast Cancer Database of the Mayo Clinic, in a 
group of 179 breast cancer patients with recurrence of 
lung metastases, 29 patients were reported to have had 
a diagnosis of asthma at least one year prior to the diag-
nosis of distant metastases, suggesting that this condition 
may have contributed as a risk factor for lung metasta-
ses [6]. Indeed, there are key features associated with 
asthma-related inflammation and especially the presence 
of eosinophils. These cells can clearly contribute to anti-
cancer immunity by modifying the microenvironment 
and promoting tumor rejection after T cells infiltration 
[7], as well as represent indicator of success of therapies 
against cancer [8]. However, (to date scarce) evidence 
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exists regarding the potential role of eosinophilic inflam-
mation in the establishment of lung metastasis of cancers. 
Immune cells produce indeed a subset of chemokines 
[9], especially the cytokine CCL11 which is abundantly 
produced in the lungs of patients with asthma and also 
widely expressed in other human tissues including heart, 
colon, kidney, small intestine, pancreas, liver, and ovaries. 
CCL11 binds to CCR3, a seven-transmembrane domain 
that activates a number of signaling  pathways. This 
cytokine is best known as an eosinophil-selective chem-
oattractant cytokine [10], that might also display effects 
on neutrophils, [11] although it was recently reported 
that chemokine receptors (iCCRs) exert no significant 
effects on neutrophils [12]. Until now, CCL11 implica-
tion in cancer progression has been scarcely investigated. 
CCL11 has also been proposed as a biomarker in differ-
ent types of cancers with however still little evidence that 
CCL11 or CCR3 expression may serve as a prognostic 
factor in cancer [13–15]. Earlier studies showed the role 
of CCL11 in tumor cells migration, tissue invasion and 
angiogenesis in ovarian cancer [15]. Chemical inhibitors 
of CCR3 (SB-297006 or (S)-ethyl-2-benzoylamino-3-(4-
nitrophenyl) propionate) have an impact on CCL11-
induced migration of mouse neural progenitor cells, as 
well as on photoreceptor-derived cell line [16–18]. Dif-
ferent cytokines are now therapeutic targets in asthma 
with different treatments on the market targeting IL5 or 
IL4 and IL13 receptor and other products in develop-
ment that comprise CXCR2 antagonists or low molecu-
lar weight chemicals that antagonize CCL11 receptor, 
cysteine-cysteine chemokine receptor-3 (CCR3) [19–21]. 
As these potent medications allow the control of severe 
forms of asthma, it is important to unveil any potential 
link between asthma-related inflammation and possible 
mechanisms triggering pulmonary metastases.
Methods
Cell culture
Murine mammary tumor cells 4T1 (clone 1A4) sta-
bly transfected with luciferase gene were purchased 
from Caliper Life Sciences. Mammary tumor cells were 
grown at 37 °C, in 5%  CO2, in Dulbecco’s Modified Eagle 
Medium (Invitrogen Corp. /Life Technologies, Gent, 
Belgium) supplemented with 10% fetal bovine serum 
and 2  mmol  l−1 L-glutamine, penicillin–streptomy-
cin (100  IU  ml−1—100  µg  ml−1) (Invitrogen Corp. /Life 
Technologies).
Mice
Male Balb/cJRj mice, 6 to 8  weeks old, were purchased 
from Charles River (Cologne, Germany). All animal 
experimental procedures were approved by the ethical 
committee of the University of Liège. Food and water 
were supplied ad libitum.
Experimental asthma protocol
In the OVA-induced inflammation model, mice were 
immunized by i.p. injection of OVA (10  μg; Sigma-
Aldrich, Schnelldorf, Germany) and aluminum hydroxide 
on days 1 and 11. From days 21 to 67, mice were exposed 
to inhalation of 1% OVA or PBS for 30 min. Mice chal-
lenged with PBS were used as controls (control litter-
mates). At day 45, luciferase-expressing 4T1 cells (2 × 105 
cells/200 μl of serum-free medium) were subcutaneously 
injected into flanks of mice (n = 8 mice/group). Volume 
of primary tumor growth was evaluated on days 20, 23 
and 25 with a caliper. In vivo, lung metastases were quan-
tified by bioluminescence measurement after intraperi-
toneal injection (i.p) of D-luciferin (150  mg/kg in PBS; 
Promega, Madison, WI) using the IVIS® 200 Imaging 
System (Caliper Life Sciences, Hopkinton, MA). Quan-
titative assessment of lung metastasis was performed by 
determining “regions of interest” (ROI) by measuring 
bioluminescence intensity using Living Image software.
Experimental CCL11 protocol
Mice (n = 6/group) were anesthetized with 2.5% isoflu-
rane/oxygen mixture and intratracheally (i.t) injected 
with Phosphate Buffered Saline (PBS) or recombinant 
CCL11 (10  ng/ml PBS, R&D System, MN), 3 times per 
week. After 4 i.t instillations, murine mammary cancer 
4T1 cells (1 × 105 cells/50 μl of serum-free medium) were 
injected into the tail vein of Balb/c mice.
At the end of each experimental protocol, animals 
were sacrificed and bronchoalveolar lavage fluid (BALF) 
was performed via intratracheal instillation of 4 × 1  ml 
PBS-EDTA 0.05  mM solution (Calbiochem, Darmstadt, 
Germany). BALF supernatant was collected for pro-
tein assessment while cells were used for differential cell 
counts. Differential cell counts based on morphologic 
criteria were carried out on cytocentrifuged prepara-
tions after staining with haematoxylin–eosin (Diff-Quick, 
Dade, Belgium).
Pulmonary histology
Left main bronchus was clamped, excised and preserved 
at -80ºC. The right lung was infused at a pressure of 
25 cm with 4% paraformaldehyde and embedded in par-
affin. Six sections of 5 μm were randomly sectioned and 
stained with hematoxylin and eosin (H.E). Each subse-
quent section was spaced 50 μm from the previous one. 
Lung tumor development was evaluated by measuring 
lung tumor area and reporting it to the total area of lung 
tissues analyzed, on eight randomly selected H.E sec-
tions per animal in each experimental group using the 
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open source Cytomine software (http://www.cytom ine.
be, GIGA, Liège University Research Center, Belgium). 
This software implements a machine learning algo-
rithm which provides automatic tumor detections that 
were manually reviewed and edited by an experimented 
observer blinded to experimental details [22].
Measurement of cytokines by Elisa
CCL11 ELISA kits were used according to the manufac-
turer’s instructions (Duoset; R&D Systems McKinley Pl 
NE, MN).
Chemotaxis assay
Chemotaxis assay was performed using 24-Well tran-
swell plates (Corning® Costar®). In the lower well of the 
Boyden chamber assay, Bovine serum albumin (BSA) 1% 
diluted in DMEM (Life Technologies, Gent, Belgium) 
supplemented with 1% FBS was used as control. Recom-
binant CCL11 (100  ng/ml) diluted in DMEM BSA 1% 
and FBS 1% supplemented or not with CCR3 antagonist 
(SB-297006; 1  µM) was used to measure chemotactic 
potential. In the upper well, 4T1 cells (1 × 105 cells/well) 
or neutrophils (4 × 105 cells/well) were loaded, in serum-
free DMEM supplemented with BSA 0.1%, on polycar-
bonate filter pore size of 8 µm or 5 µm respectively. After 
a period of incubation of 16 h at 37 °C for tumor cells and 
4  h for neutrophils, cells were fixed (Methanol, -20  °C) 
and stained with Giemsa 4%. The migrated cells on the 
reverse side of the filter were mounted on slide, digitized 
(Hamamatsu, NanoZoomer 2.0-HT series, Shizuoka, 
Japan) and quantified with Image J software (National 
Institutes of Health, Bethesda, MA). Migrating cells were 
counted on eight random fields and the average value was 
used as an individual score for each membrane.
Mouse neutrophils isolation
In order to recover lung neutrophils using the "FACS 
aria", mice (n = 6) received intra-tracheal instillations 
of recombinant CCL11 (10  ng) on J0, J2, J5, and J7 and 
were sacrificed on J8. Lungs were incubated for 45  min 
with shaking at 37 °C in medium without serum and IV 
collagenase (1  mg/ml) (Gibco, Belgium). After homog-
enization, FBS was added in equal volume to neutralize 
collagenase IV. Samples were centrifuged at 335  g for 
5  min and treated by addition of "Red Blood Cell Lys-
ing Buffer" (Sigma, Germany). The samples were then 
separated into several phases on Histopaque® medium 
(Sigma, Germany). The granulocyte phase was stored and 
washed in PBS 2% FBS. Neutrophils ("high" SSC; "low" 
FSC) were labeled with antibodies  (CD45+,  CD11b+, 
 Gr1+,  CCR3+). On the basis of these markers, cells were 
isolated using the "FACS Aria with a purity of 93.92%. 
Once recovered, the cells were fixed on a slide (CytoSpin; 
Statspin Cytofuge 2; Iris, USA) to confirm they are 
neutrophils.
Flow cytometry
Mice lungs were dissected and incubated in a digestion 
medium containing RPMI 1640 (Roswell Park Memorial 
Institute; Lonza, Braine-l’Alleud, Belgium) supplemented 
with 1  mg/ml collagenase type IV (Life Technologies, 
Gent, Belgium) and 20  µg/ml DNase I (grade II from 
bovine pancreas; Roche, Vilvoorde, Belgium). Recovered 
cells were incubated with FcR blocking antibody (anti-
CD16/CD32, clone 2.4G2, B&D Biosciences, Erembode-
gem, Belgium) to reduce nonspecific binding. 4T1 cells 
were also labelled with Annexin FITC-PI to determine 
cell viability. The following antibodies were used to iden-
tify mouse granulocytes subpopulations: V450 Horizon-
conjugated anti-CD45, FITC-conjugated anti-CCR3, 
PE-conjugated anti-CD11b, PerCP-CY5.5-conjugated 
anti-GR1 (B&D Biosciences, Erembodegem, Belgium). 
Flow cytometry data acquisition was performed on FACS 
Canto II (B&D Biosciences) where 1 × 106 events were 
analyzed per sample and BD FACS Diva software was 
used for data analysis.
Proliferation assay
The Cell Proliferation ELISA BrdU (colorimetric) assay 
Kit (Roche Applied Science, Vilvoorde, Belgium.) was 
used to evaluate cell proliferation of 4T1 cells according 
to the manufacturer’s protocol. 4T1 cells (2000 cells/well) 
were plated on a 96-well plate in DMEM 1% FBS (con-
trol), CCL11 recombinant (100 ng/ml) supplemented or 
not with CCR3 antagonist (SB-297006; 1 µM) for 72 h.
Statistical analysis
Reported values are expressed as mean ± SEM. Statistical 
analysis differences between experimental groups were 
assessed using Instat software (GraphPad). Data were 
analyzed by Student’s t-test or one-way Anova. Varia-
tions were considered to be statistically significant at a *p 
value < 0.05.
Results
Allergen exposure promotes migration of breast cancer 
cells to the lungs
In order to analyze the effects of inflammation elicited 
by allergen exposure on metastatic dissemination of 
tumor cells, Balb/c mice were sensitized and exposed to 
inhaled  OVA or PBS from day 21 to 67 and were sub-
cutaneously (s.c) injected with 4T1 cancer cells (murine 
breast cancer cells of Balb/c background) on day 45 
(Fig.  1a). While no differences were observed between 
groups regarding subcutaneous primary tumor growth 
(Fig.  1b), histology performed at the time of sacrifice 
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confirmed that area occupied by metastases in lungs of 
mice exposed to OVA aerosols was higher as compared 
to PBS-exposed animals (n = 8, Fig. 1c, d).
CCL11 levels are elevated in BALF after allergen exposure 
and contribute to lung inflammation
Analysis of BALF of mice challenged with OVA showed 
predominantly macrophages and eosinophils. In mice 
challenged with OVA and s.c injected with 4T1 cells 
(n = 8), elevated amounts of eosinophils and neutro-
phils were measured (Fig.  1e; Table  1). CCL11 is a key 
mediator in asthma and levels of this protein were 
measured by Elisa in lung tissue extracts. OVA-chal-
lenged animals displayed significantly higher CCL11 
levels as compared to control mice (Table  1). 4T1 cells 
extracts contained detectable levels of CCL11 as meas-
ured by Elisa (18.68 pg/ml of cell extract). In an ex-vivo 
experiment in Boyden chambers, recCCL11 significantly 
increased neutrophils migration (after 4 h) as compared 
to PBS (Fig.  1f *p < 0.05). To confirm the influence of 
recCCL11 on lung neutrophils migration in  vivo, naïve 
BALB/c mice were IT instilled with recCCL11. After 
24 h, CCL11-treated animals displayed large amounts of 
neutrophils in BALF (19.8% ± 4.43; n = 3).
Lung histology at day 67
PBS exposed - 4T1 OVA exposed - 4T1
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Fig. 1 Inflammation generated by OVA challenge induces tumor cell dissemination to the lung parenchyma (n = 8/group). a Timeline of mice 
challenged with OVA and s.c injected with 4T1 cells. b Volume of subcutaneous primary tumor. c, d Tumor size quantification assessed by 
measuring the ratio between the area of tumor foci in lungs and total lung tissue area on 8 sections per mouse in each group. Scale bar: 2 mm 
(hematoxylin–eosin). Results are expressed as mean tumor area/lung area ± SEM and are representative of 2 individual experiments. OVA indicate 
ovalbumine; PBS, phosphate-buffered saline (e) representative BALF total cell of mice exposed to OVA and subcutaneously injected with 4T1 
cells. Scale bar: 50 µm (hematoxylin–eosin). f Quantification of isolated neutrophils migrating to a gradient of recCCL11 during 4 h using Boyden 
chamber assay. Neutrophils migration was estimated on 16 random fields (20 ×) of triplicate wells.*p < 0.05
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CCL11 promotes tumor cells migration to lung parenchyma
To evaluate whether CCL11 might promote tumor cells 
migration to lung parenchyma, mice were intravenously 
injected with 4T1 cells after intratracheal instillation of 
recombinant CCL11 (recCCL11) (Fig.  2a). Luciferase 
activity in lungs corresponding to the presence of 4T1 
cells and measured the day of sacrifice (J + 6) was signifi-
cantly higher in recCCL11-treated mice as compared to 
the corresponding control groups (Fig. 2b, c; **p < 0.01). 
Histological analysis confirmed that the area occupied by 
metastases in the lungs of recCCL11-treated mice was 
significantly higher as compared to PBS-instilled mice 
(Fig.  2c, d; n = 6; **p < 0.01). Elevated neutrophil counts 
were measured in BALF of recCCL11-treated mice sub-
cutaneously injected with tumor cells (Table 2).
CCL11–CCR3 interaction induces 4T1 cells migration 
and proliferation
Both 4T1 tumor cells and neutrophils isolated from lung 
parenchyma displayed significant CCR3 expression as 
measured by FACS (Fig. 3a-c). The strategy used Annexin 
V signal that provides a very sensitive method for detect-
ing cellular apoptosis, while propidium iodide (PI) was 
used to detect necrotic or late apoptotic cells, char-
acterized by the loss of integrity of plasma and nuclear 
membranes. This cellular staining allowed discriminat-
ing viable cells which are negative with both probes (PI/
FITC -/-; Q3). On this basis, it is possible to differentiate 
the percentage of viable 4T1 tumor cells (13.8%) express-
ing the CCR3 receptor on their surface. Furthermore, in 
order to obtains counts of pulmonary neutrophils, lung 
lysate of mice treated with intratracheal instillation of 
recCCL11 was sorted by FACS Aria according to the 
CD45 + / GR1 + /  CD11bhi labeling. In this population, 
neutrophils positive for CCR3 have been discriminated 
(31.5%). Inhibition experiments were performed in vitro 
in order to understand whether 4T1 cells migration and 
proliferation were driven by a CCL11–CCR3 interaction. 
Interestingly, tumor cells migration measured in Boyden 
chambers was decreased when culture medium was sup-
plemented with the CCR3 antagonist SB-297006 (Fig. 4a; 
*p < 0.05). Proliferation of tumor cells was significantly 
reduced after 72  h arguing for a direct effect of CCL11 
on CCR3 that in turn promotes cell proliferation (Fig. 4b; 
*p < 0.05).
Discussion
This study with potential important clinical impli-
cations was performed in order to identify poten-
tial mechanisms that might explain how pre-existing 
lung parenchyma allergen-driven inflammation could 
enhance metastasis. We previously reported that 
elevated lung levels of PGP tripeptide (collagen frag-
ments produced after collagen cleavage by inflamma-
tory cells-derived MMP9) trigger lung metastasis [23]. 
Other authors also reported about the potential role 
of pro-inflammatory mediators in tumor progression 
and genesis of metastases [24]. In this study, the main 
purpose was to verify the hypothesis that allergen-
induced inflammation has the capacity to generate a 
burden of cancer cell metastasis in lung parenchyma. 
Indeed, to the best of our knowledge, there is no study 
to date reporting a correlation between asthma and 
lung metastasis of breast cancer, while some epide-
miological studies suggest that allergic diseases might 
be associated with an increased risk of breast cancer 
Table 1 Differential cell counts (percentages) in  the  bronchoalveolar lavage fluid after  treatment with  PBS or  OVA 
inhalation and subcutaneous injection of 4T1 cells
Proteins level expression of CCL11 (pg/ml) in lung of mice exposed to PBS or OVA and subcutaneously injected with 4T1 cells. *p < 0.05, **p < 0.01.
Differential cell counts
n = 8 INH INH + 4T1 subcutaneous injection
Cell type PBS OVA PBS OVA
Eosinophils 3.53 ± 0.39 29.5 ± 5.74 11 ± 1.86 17.3 ± 5.15
Neutrophils 6.1 ± 1.43 5.46 ± 1.39 27.35 ± 1.74 46.31 ± 5.16**
Lymphocytes 0.10 ± 0.10 0.0 ± 0.0 0.0 ± 0.0 0.77 ± 0.43
Epithelial cells 5.83 ± 1.93 5.13 ± 1.72 1.62 ± 0.69 2.81 ± 0.97
Macrophages 84.3 ± 2.8 59.7 ± 4.3* 59.9 ± 2.76 32.63 ± 6.6**
Proteins level expression of CCL11
n = 8 INH INH + 4T1 subcutaneous injection
CCL11 (pg/ml) PBS OVA PBS OVA
Mean ± SEM 0,21 ± 0,04 0,58 ± 0,12* 0,36 ± 0,07 0,42 ± 0,08
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[25]. Moreover, epidemiological studies suggest an 
increased risk of lung cancer as a possible consequence 
of changes in lung microenvironment promoted by 
asthma-related inflammation [26–28]. In the present 
study, we report that OVA-generated inflammation 
triggers the implantation of metastatic cells into lung 
tissue, probably in a CCL11–CCR3–dependent man-
ner. This is indeed supported by (i) the measurement of 
increased cancer cells dissemination to lungs of Balb/c 
mice immunized and challenged with inhaled ovalbu-
min; (ii) the higher expression of CCL11 in lungs of 
mice OVA-challenged and subcutaneously injected 
with 4T1 cells; (iii) the stimulation of neutrophils and 
4T1 cells migration by the use of rec CCL11 in  vitro 
and in  vivo; (iv) the flow cytometry studies showing 
that CCR3 is expressed by 4T1 cells and neutrophils; 
(v) the abolishment of CCL11-induced 4T1 cells migra-
tion and proliferation when cells are incubated with a 
CCR3 selective antagonist. Our results are concordant 
with a study showing that allergen-induced pulmonary 
inflammation resulted in an increase in lung metastases 
of B16F10 melanoma cells [6] and we propose a mecha-





























































































Fig. 2 Intratracheal injection of CCL11 recombinant (recCCL11) induces 4T1 tumor cell migration to lung tissue (n = 6/group). a Timeline of 
experiment. Mice were challenged with i.t of recCCL11 and i.v injected with luciferase-stably transfected 4T1 cells. b, c On day 15, biophotonic 
monitoring of lung metastasis in animals and quantification of bioluminescence in regions of interest (ROI) determined around lungs. d, e 
Representative hematoxylin–eosin–stained sections of lung tissues and tumor size quantification assessed by measuring the ratio between the area 
of tumor foci in lungs and total lung tissue area on 8 sections per mouse in each group. Scale bar: 2.5 mm, 100 µm. Results are expressed as mean 
tumor area/lung area ± SEM. **p < 0.01
Table 2 Differential cell counts (percentages) 
in  the  bronchoalveolar lavage fluid after  treatment 
with  PBS or  recCCL11 and  intravenous injection of  4T1 
cells
*p < 0.05, ***p < 0.001
n = 6 IT + intravenous injection
Cell type PBS CCL11
Eosinophils 0.65 ± 0.33 5.25 ± 1.06*
Neutrophils 5.96 ± 1.5 52.98 ± 1.72***
Lymphocytes 0.0 ± 0.0 0.0 ± 0.0
Epithelial cells 12.08 ± 3.45 2.36 ± 0.99*
Macrophages 81.18 ± 3.2 39.28 ± 2.13***





























































































































Neutrophils of mice treated with intratracheal instillation of RecCCL11 
4T1 Cells
Fig. 3 Measurement of CCR3 on 4T1 cells and neutrophils by flow cytometry. a The dot plot diagrams represent typical apoptotic and necrotic 4T1 
cell populations detected by Annexin V-FITC and PI staining. The lower left quadrants (Q3; 49.2%) of the panels show viable intact cells, which were 
negative for Annexin V-FITC binding and excluded PI staining (FITC-/PI-); the upper right quadrants (Q1; 7.5%, Q2; 32.1%) show nonviable, necrotic 
cells, which were positive for Annexin V-FITC binding and PI uptake (FITC + /PI +). The lower right quadrants (Q4; 11.2%) represent apoptotic cells, 
positive for Annexin V-FITC and negative for PI (FITC + /PI-). b Representative histograms for flow cytometric analysis of surface expression of CCR3 
receptors on 4T1 cells. IgG: Isotype control. c Lung neutrophils of mice treated with intratracheal instillation of recCCL11, sorted by FACS Aria
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Asthma is a chronic inflammatory disorder resulting 
from a complex interaction between inflammatory cells, 
mediators and airway structural cells. CCL11 is one of 
the key cytokines of the cascade of inflammatory media-
tors leading to an established allergen-driven airway 
inflammation. Importantly, we demonstrate for the first 
time that 4T1 cells express CCR3 and are in  vitro and 
in vivo sensitive to CCL11.
In our experimental setting, we cannot rule out that 
other mechanisms or other cell types could play a role 
in the increased dissemination of cancer cells. Hence, 
mast cells activation during anaphylaxis was reported 
to increase mouse melanoma cells dissemination in an 
HDAC3-dependent manner [29] and mast cells have 
been shown to increase growth of Hodgkin lymphoma 
tumors and plasma cell tumors [30, 31]. Also, NETs-pro-
ducing neutrophils also play crucial roles in cancer dis-
semination to the lung [32]. Recent studies performed 
on mice depleted for iCCRs did show that these recep-
tors are not involved in neutrophils recruitment in acute 
inflammatory conditions [12]. The increased number 
of neutrophils in the BAL of mice injected with 4T1 is 
expected and not modified whether mice were exposed 
to OVA or PBS. Indeed, 4T1 mammary tumors were 
reported to induce an accumulation of neutrophils in 
various organs including lung parenchyma [33]. This 
has been reported previously by different authors and it 
was shown that these cells produce the c-Kit ligand, SCF 
and are able to expand a specific population of myeloid 
cells (Ly6Ghi Ly6Clow c-Kit +) [34, 35]. The relationship 
between neutrophils and cancer dissemination is com-
plex. Indeed, our group previously reported that 4T1 
cells produce a soluble factor inducing the production of 
IL16 by neutrophils and, in turn, this cytokine promotes 
in  vitro 4T1 cell adhesiveness, invasiveness, and migra-
tion [33].
In conclusion, we report that allergen-induced inflam-
mation triggers metastatic dissemination to lung paren-
chyma by activating the CCL11–CCR3 pathway. This 
should be assessed in human in observational cohorts 
and by retrospective analysis of results of clinical trials.
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Fig. 4 Measurement of CCR3 antagonist (SB-297006) effects on 4T1 cells migration and proliferation. a Quantification of 4T1 tumor cells 
chemotaxis, using Boyden chamber assay, supplemented with recCCL11 and CCR3 antagonist (FBS1%: n = 8. FBS 1% + RecCCL11: n = 6 and FBS 
1% + RecCCL11 + SB: n = 5), after 16 h. b After 72 h, proliferation of 4T1 cells treated with recCCL11 and CCR3 antagonist was assessed using 
BrdU staining (FBS 1%: n = 16, FBS 1% + RecCCL11: n = 14 and FBS 1% + RecCCL11 + SB: n = 14). Results are expressed as mean ± SEM. *p < 0.05, 
***p < 0.001
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